SOURCE: IDenta Corp.

March 15, 2010 10:00 ET

International Drug & Explosives Detection Firm IDenta Corp. Reports on Law Enforcement Agencies in the US

JERUSALEM--(Marketwire - March 15, 2010) - IDenta Corp. (PINKSHEETS: IDTA) CEO Yaacov Shoham released today the following information from Jant Pharmacal Corporation, Identa's US representative:

Reported from Jant:

"A 1. The new Ammonium Test kits (EX377) we received last Friday have been sent to all the contacts we discussed, including TSA, ATF, Naval EOD Technology Division, GE, and a few contacts of the US Army testing sites that have contacted us in February. We are planning to follow up with calls next week. The ex377 - Ammonium Test Kit is the new identifying explosive kit developed by Baruch Glattstein for the US army in Afghanistan.

"2. The client we met with in Chicago (in the last few months we have been in intensive dialogue with this company) is a very large multi-national concern.

"They have confirmed the explosive detection presentation that will be held on Friday, March 19th:

"So far they have 40 Municipal, County, State, Federal and Private Agencies decision makers signed up for the breakfast meeting/presentation. This is coordinated with the local FBI bomb unit that has already purchased some kits for evaluation and had a very positive feedback ("one of the best kits he ever saw in the market").

"Jant Pharmacal will have about 30 minutes to present the material. We will email Baruch a copy of the powerpoint, to review by the end of this week for his suggestions and comments.

"3. We are currently reviewing the contract draft (WITH CHICAGO BASED COMPANY) they sent us and are planning to move forward on our negotiations, following the terms we have agreed with you:

"Private label exclusivity (other than Accutest IDenta) for the US, Initially for 2 years based on at least the following quantities:

-- Year 1: Drugs tests 155,000 tests / Explosive tests 75,000

-- Year 2: Drug tests 200,000 / Explosive tests 150,000

"The expected income from this company in the first two years will be about, $1,500,000.

"Our goal is to sign very soon a tri-party agreement with them involving (a) Manufacturer -- IDenta b) Supplier -- Jant c) Our Client/Distributor.

"They also have already started the evaluation of the 500 drug tests we sent them (Cocaine/Heroin/Ecstasy/Marijuana) and have done extensive market research comparison with other technologies. They have even begun artwork design for the different kits."

B. The final decision for the tender (100,000 explosive kits to be used by the US army in Afghanistan) will be probably this coming week.

IDenta is confident that we will receive the tender, because we are the only company able to provide this new Ammonium Test Kit -- ex377.

See the press release from March 2, 2010.

Shoham also commented, "These activities are only a part of IDenta's global activities and acceptance of our kits has been tremendous. However these large companies and agencies work on their own timeline and sometimes delays occur. We will continue to update finalization of contracts as they occur." Shoham also announced that "We have found out that the shares of IDenta have been shorted heavily in the past and recently by some different people. Last week for example we have been shorted as follows on 3/10 and 3/11 and we are working to address the 'shorting issue'."

Date      Symbol       ShortVolume       TotalVolume     Market     Percent


20100310  IDTA         2,729,997         4,879,774       O          55.95%

20100311  IDTA         799,000           3,177,568       O          25.15%

Information concerning IDenta's entire product line may be found at www.IDenta.biz

ABOUT IDENTA

Since 2003, IDenta Corporation has been recognized as a worldwide leader in the development of proprietary on-site drug, drug precursor and explosive detection kits. IDenta develops, manufactures and distributes products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

DISCLAIMER

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

For Investor Relations, lobbying interests or information concerning IDenta's products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com, www.identa.biz.

For information about the Accutest® - IDenta products in the US, please contact: Mr. Eyal Golan, Manager, Business Development,, JANT PHARMACAL CORPORATION, 16255 Ventura Blvd. #505, Encino, CA 91436, Toll Free: 800-676-5565, 661-478-0582 (mobile), golan@accutest.net, www.accutestidenta.net.

Contact Information